Ultra-hypofractionated Radiation in Prostate Cancer

Prior treatment

• Current or anticipated use of other investigational agents while participating in this study.
• Prior pelvic radiation therapy
• Prior prostatectomy

Other illness

• Psychiatric illness/social situations that would limit compliance with study requirements
• Inflammatory bowel disease or connective tissue disease requiring medical management

• Ability of participant to sign a written informed consent.
• Diagnosed with prostate cancer, T1-T2bN0M0 GS6-7, PSA \< 20
• IPSS score \< 15 (and \< 10 if on medication for benign prostatic hypertrophy such as tamsulosin) at time of enrollment (Appendix 21.4)
• Prostate volume (by US, CT or MRI measurement) \< 50 cc at time of enrollment
• Androgen deprivation therapy based on clinician judgment is permitted on study
• Life expectancy \> 10 years based on clinician's judgment
• No other active malignancy
• Age ≥ 18 years
• Performance Status Eastern Cooperative Oncology Group (ECOG) 0-1 (Appendix 21.5).
• Other study-specific criteria:
• Men of child-bearing potential must not donate sperm while on this study and for 90 days after their last study treatment.
  • NOTE: Acceptable forms of birth control are listed below:
• One Barrier method (cervical cap with spermicide plus male condom; diaphragm with spermicide plus male condom) PLUS
• Hormonal method (oral contraceptives, implants, or injections) or an intrauterine device (e.g., Copper-T).